Federated Hermes
LRMR icon

Federated Hermes’s Larimar Therapeutics LRMR Stock Holding History

Federated Hermes’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
90,850
+29,500
+48% +$117K ﹤0.01% 1466
2026
Q1 		$276K Sell
61,350
-297,557
-83% -$1.19M ﹤0.01% 1438
2025
Q4 		$1.37M Buy
358,907
+356,512
+14,886% +$1.39M ﹤0.01% 1043
2025
Q3 		$7.74K Sell
2,395
-260
-10% -$975 ﹤0.01% 1904
2025
Q2 		$7.67K Buy
+2,655
New +$6.15K ﹤0.01% 1850
2024
Q4 		– Sell
-3
Closed -$20 – 2146
2024
Q3 		$20 Buy
3
+2
+200% +$16 ﹤0.01% 2037
2024
Q2 		$7 Buy
+1
New +$8 ﹤0.01% 2008
2020
Q2 		– Sell
-2
Closed -$1K – 2317
2020
Q1 		$1K Sell
2
-2
-50% -$26 ﹤0.01% 2122
2019
Q4 		$1K Hold
4
– – ﹤0.01% 2114
2019
Q3 		$1K Sell
4
-5
-56% -$55 ﹤0.01% 2114
2019
Q2 		$1K Sell
9
-39
-81% -$1.04K ﹤0.01% 2115
2019
Q1 		$2K Sell
48
-159
-77% -$8.15K ﹤0.01% 2068
2018
Q4 		$12K Sell
207
-37
-15% -$3.65K ﹤0.01% 1849
2018
Q3 		$34K Sell
244
-3
-1% -$364 ﹤0.01% 1786
2018
Q2 		$30K Sell
247
-3,931
-94% -$334K ﹤0.01% 1751
2018
Q1 		$373K Sell
4,178
-3,020
-42% -$256K ﹤0.01% 1434
2017
Q4 		$399K Sell
7,198
-245
-3% -$11K ﹤0.01% 1415
2017
Q3 		$314K Sell
7,443
-3,326
-31% -$138K ﹤0.01% 1437
2017
Q2 		$454K Buy
10,769
+3
+0% +$153 ﹤0.01% 1400
2017
Q1 		$602K Sell
10,766
-39
-0.4% -$1.94K ﹤0.01% 1294
2016
Q4 		$412K Buy
10,805
+2,294
+27% +$93K ﹤0.01% 1365
2016
Q3 		$338K Buy
8,511
+1,446
+20% +$65.7K ﹤0.01% 1384
2016
Q2 		$508K Buy
7,065
+7,056
+78,400% +$558K ﹤0.01% 1272
2016
Q1 		$1K Hold
9
– – ﹤0.01% 2029
2015
Q4 		$1K Buy
+9
New +$1.45K ﹤0.01% 2019

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Federated Hermes's LRMR Position: Q2 2026 in Review

Federated Hermes increased its Larimar Therapeutics (LRMR) stake by 48% in Q2 2026, buying an estimated $117K and bringing the position to 90,850 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

Federated Hermes first reported a position in LRMR in Q4 2015 and has held it in 25 quarters since. The position peaked at $1.37M in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Federated Hermes held 90,850 shares of Larimar Therapeutics worth $277K as of Q2 2026.
  • Federated Hermes bought 29,500 Larimar Therapeutics shares in Q2 2026, an estimated $117K.
  • Larimar Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1466 holding.
  • Federated Hermes first reported a position in Larimar Therapeutics in Q4 2015 and has held it in 25 quarters since.
  • Federated Hermes's Larimar Therapeutics position peaked at $1.37M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.